Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Neurodegenerative Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HSP90 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HSP90AA1 Recombinant Protein (Full-Length / N-Terminal Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for ATPase assays and SPR binding kinetics. |
View HSP90AA1 Products |
| Gene Delivery | HSP90AA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to evaluate client protein degradation in cell-based assays. |
View HSP90AA1 Products |
| Benchmark Ab | Anti-HSP90AA1 Recombinant Antibody Recombinant positive control matching clinical reference sequence parameters for assay validation. |
View HSP90AA1 Products |
| Validator | HSP90AA1 siRNA Set Target-specific knockdown verification to validate phenotypic assay specificity. |
View HSP90AA1 Products |
| Related Target A | HSP90AB1 (HSP90 Beta) Constitutively expressed cytosolic isoform. Essential for counter-screening to determine isoform selectivity. |
View HSP90AB1 Products |
| Related Target B | AKT1 Crucial HSP90 client protein. Monitoring AKT degradation serves as a functional readout for HSP90 inhibition. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (Alpha vs. Beta vs. GRP94) | Human HSP90AA1, HSP90AB1, and GRP94 (HSP90B1) ortholog proteins available with >95% purity verified by SDS-PAGE. |
| ATPase Assay High Background | Low-endotoxin, high-purity recombinant proteins expressed in eukaryotic systems to preserve native conformation and minimize assay interference. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control reagents included in the portfolio. |
| Off-Target Phenotypes | Validated siRNA sets included for target-specific knockdown to confirm on-target therapeutic mechanisms. |
Live HSP90 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HSP90 therapeutics is intensifying, with major players shifting focus from traditional pan-HSP90 inhibitors to isoform-selective molecules and chaperone-mediated degraders (PROTACs). As first-generation pan-inhibitors faced clinical hurdles due to dose-limiting toxicities (such as ocular and hepatotoxicity), the next wave of R&D is targeting specific cytosolic isoforms (HSP90AA1 vs. HSP90AB1) or utilizing HSP90-binding moieties to direct targeted protein degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Isoform-Selective Small Molecule | Samus Therapeutics, Esanex | Solid Tumors, Neurodegenerative Diseases | Selectivity Assay (Need high-purity HSP90AA1 and HSP90AB1 proteins for comparative SPR) |
| PROTAC / Chaperone Degrader | Arvinas, Kymera Therapeutics | Breast Cancer, Prostate Cancer | Degradation Kinetics (Need Lentivirus for stable cell lines expressing tagged client proteins) |
| C-Terminal Domain Inhibitors | Academic Consortia, Biotech Startups | Refractory Cancers | Domain-Specific Binding (Need truncated C-terminal recombinant proteins) |